CEO says, "take this" for Shareholder Value. He better starts building EXEL for success.
If not, he would need to sell another 300 Million at $2.00 for raising Capital. This is the most Moronic Individual I am seeing today. He gutted shareholders confidence in his ability to manage. He filled up his pockets, gets pay and Bonuses and it is the only stock in the whole markets which went down instead of going up in Record High's market. Why? He better starts before this stock declines further and he must dilute again. His ability to attain Partners is lacking, Clearly he just canno't shove shareholder Value down our throats with a Dead stock. I have seen the difference with Scangnos and this Mike Moron. Scangnos had extreme abilities to gain partners. Since he left this Company have gone to the dogs. Not one new Partner since Scangnos left. It is disheartening to know that we have so much going on , and nothing but Diluting is happening to this Company. Some ways I believe Scangnos would have already sold Exel or partnered. Just look at Scangnos and the Company he tok over BIIB. It has almost trippled. Mike is a complete let down who is lacking in ability to sell our Products. It is why this stock is heavily shorted. Shorts knows that without any Partnership, they must dilute again. Morrison needs to be kicked in the balls or for that matter this board eeds to all blow themselves up. They are failing this Company.
I happen to own one biotech stock (same as EXEL: one pony with many tricks). That company has only one product with multiple indications (sell animal hormone extracted from pig's pituitary gland). That used to be penny stock company bought that only drug from another big pharma (?10,000 dollars) several years ago. The CEO was so brilliant that he turned that penny stock company into one of the best in S&P 500 company in the past 3 years. Like EXEL, that company was also heavily shorted (50% of floaters) and targeted by Citron since last year, but the CEO came out buying back shares from open market, pay dividends, expending other medical indications for that only drug, and purchasing shares from open market using his own millions' dollars. I took position on that company not because of that drug (hormone extracted from pig's pituitary glands) but because of that CEO's capability. Now look at this guy from EXEL, did he ever (even once) come out do something or say anything on behalf of left alone shareholders? Did he ever purchase even one share from the open market using his own money? He had his mouse shut like turtle when spoke for the company's share value in front of street. He is good at diluting shares and adding up his own compensation plus exercising his option as fast as he could! Why do we need him? Without him Cabo will still do the fine job by saving life and bringing hopes to patients. What we need right now is Carl Icahn.
"Presently, this company's stock is trading too cheap considering the cash and value of the portfolio"
Considering Cabo's clinical performance to date, cash-on-hand, and the P1 efficacy of GDC-0973 - it smells more and more as though a strategic entity is "sitting on " the PPS. We have P1 interim reporting of the Cabo/Abi combo from the AACR in approx 17 days. We already know the trial is opening up to a prechemo population, indicating early results have been productive...possibly even favorable...and - at best - additive and synergystic - moving Cabo into a frontline setting in PC.
If the published interim reporting is favorable next month for the Abi combination trial, how could there be a continued rangebound PPS unless there were indeed a manipulative short-side play at hand...?? I am very suspicious right now - but any hint of synergy between Abi & Cabo that does not result in a volume/share price spike will confirm a strategic manipulation. JMHO
When GS did the offering, you knew the company got into bed with an Asp. Now it's time to slay it and move forward enhancing shareholder value. The remaining pipeline requires attention. Validation is coming for Cometriq in more than one indication and thus the pipeline from which many of EXEL's compounds are derived. Scangos was no dreamboat of a CEO. While he managed to prop up share price, he did so by partnering without late phase trials ($$$$). However, he also milked the cow every month with options and frankly, wasn't interested in selling the company. Presently, this company's stock is trading too cheap considering the cash and value of the portfolio. Big pharma should be looking here for a series of drugs to be used in cancer treatment for the next 10 years. All told, the revenue from just two drugs for multiple indications would pay for the buyout easily. Big pharma could definitely squeeze value from EXEL's property. A buyout now would look cheap in 2 years time....jmho